SABCS 2022 | APT: adjuvant paclitaxel and trastuzumab for node-negative, HER2+ breast cancer

Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, shares the final 10-year analysis of the Phase II APT (NCT00542451) trial investigating adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. The primary endpoint was invasive disease-free survival (iDFS). The 7-year results saw an IDFS of 93%, a recurrence-free interval (RFI) of 97.5% with only four (1.0%) distant recurrences, and a 7-year overall survival (OS) of 95%. After a median follow-up of 10.2 years, 36 iDFS events were observed, consistent with a 10-year iDFS of 89.7%. 10-year iDFS was 90.2% and 88.5% for patients with HR-positive and HR-negative tumors at baseline, respectively. 10-year RFI was 96.8%, 10-year OS was 94.2% and 10-year BCSS was 99.1%. The novel biomarker assay HER2DX was also assessed, which was associated with long-term outcomes. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.